Direction: Epigenetics and Translational Research
Position:Full Professor
Scientific interests / research interests
გამოქვეყნებული შრომები ბოლო 10 წლის განმავლობაში
- Adamia S, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2008;112:5111-5121. ISSN 1528-0020.
- Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008;7:1121-29. ISSN 1535-7163.
- Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009;145:59-63. ISSN 1365-2141.
- Adamia S, Pilarski PM, Belch AR, Pilarski LM. Genetic abnormalities in Waldenstrom’s
macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:30-2. ISSN 1557-9190.
- Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250-5. ISSN 1527-7755.
- Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O’Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom Blood. 2009;113:626-634. ISSN 1528-0020.
- Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther. 2010;9:2468-77. ISSN 1538-8514.
- Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, Adamia S, Wu C, Gray N, Griffin JD. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010;115:4206-16. ISSN 1528-0020.
- Weisberg E, Deng X, Choi HG, Barrett R, Adamia S, Ray A, Moreno D, Kung AL, Gray N, Griffin Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia. 2010;24:1375-78. ISSN 1476-5551.
- Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6:e25351. ISSN 1932-6203.
- Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117:4409-19. ISSN 1528-0020.
- Amin SB, Shah PK, Yan A, Adamia S, Minvielle S, Avet-Loiseau H, Munshi NC, Li C. The dChip survival analysis module for microarray data. BMC Bioinformatics. 2011;12:72. ISSN 1471-2105.
- Adamia S, Pilarski PM, Belch AR, Pilarski LM. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets. Curr Cancer Drug 2013;13:347-61. ISSN 1873-5576.
- Adamia S, Pilarski PM, Bar-Natan M, Stone RM and Griffin JD. Alternative Splicing In Chronic myeloid Leuekimia (CML): a novel therapeutic target? Current cancer drug targets, 2013 Jul 30 [Epub ahead of print]. ISSN 1873-5576.
- Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD. A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. Clin Cancer Res. 2014 Feb 11. [Epub ahead of print] PMID: 24284058.
- Adamia S, Bar-Natan M*, Haibe-Kains B*, Pilarski PM*, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone RM and Griffin JD. NOTCH2 and FLT3 gene mis-splicing are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood, 2014 Feb 26. PMID:24574459.
- Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, Adamia S, Belch AR, Pilarski LM. Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not breast cancer. PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.
- Cagnetta A, Adamia S, Acharya C, Patrone F, Miglino M, Nencioni A, Gobbi M, Cea M. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal Leuk Res. 2014 Mar 18. PMID: 24726781.
- Adamia S, Kriangkum J, Belch AR, and Pilarski LM. Aberrant post-transcriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression. Adv Cancer Res. 2014;123:67-94. doi: 10.1016/B978-0-12-800092-2.00003-4. PMID:25081526.
- Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2015 Dec 16. pii:blood-2015-06-649970. [Epub ahead of print] PubMed PMID: 26675349.
- Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, Adamia S, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. Clin Cancer Res. 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11. PubMed PMID: 25964294.
- Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.194. [Epub ahead of print] PubMed PMID: 26202935.
- Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2015 Dec 16. pii:blood-2015-06-649970. PMID: 26675349.
- Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13. PMID:26165234.
- Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D’Aquila P, Bellizzi D, Passarino G, Adamia S, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15;6:e380. doi: 10.1038/bcj.2015.106. PubMed PMID: 26771806; PubMed Central PMCID: PMC4742623.
- Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 Apr 12. doi: 10.18632/oncotarget. 8702. [Epub ahead of print] PubMed PMID: 27081697.
- Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, and Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2. PubMed PMID: 28967922.
- Brunner AM, Neuberg D, Wander SA, Sadrzadeh H, Ballen K, Amrein P, Attar E, Hobbs G, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, and Fathi AT. Isocitrate Dehydrogenase 1 and 2 Mutations, 2-Hydroxyglutarate Levels, and Response to Standard Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia” (CNCR-18-1219.R1) has been accepted for publication in Cancer.
- Linda M. Pilarski , Jitra Kriangkum, Sophia Adamia, Helga M. Ogmundsdottir, Andrew R. Belch. Waldenstrom’s Macrogloblinemia Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis. Book Chapter, “Waldenstrom’s Macroglobilinemia”, Springer publishing 07. October 2017, pp35-48. ISBN-13: 978-3319225838
მონაწილეობა სამეცნიერო კონფერენციებში ბოლო 10 წლის მანძილზე
ზეპირი მოხსენებები:
- 2008 Invited speaker – High-throughput microRNA profiling: Identification of miRNAs with a potential pathogenic role in Waldenstrom’s macroglobulinemia. 5 th International Waldenstrom’s macroglobulinemia workshop, Stockholm Sweden
- 2008 – miRNA Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy 50 th American Society of Hematology annual meeting, San Francisco, CA; Blood. 2008;112;
- 2009 Invited speaker at Plenary session – miRNA profiling identified distinct clinically relevant sub-groups in multiple myeloma. 12 th Multiple Myeloma workshop, Washington DC
- 2009 – Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in vitro and in vivo 51 th American Society of Hematology annual meeting, New Orleans, LA; Blood. 2009;114;
- 2010 – Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML). 52th American Society of Hematology annual meeting, Orlando, FL; Blood. 2010;116;
- 2011 – Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets. 53rd American Society of Hematology annual meeting, San Diego, California; Blood. 2011;118;
- 2012 – Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Is Associated with Altered Expression of Splicing Factors. 54th American Society of Hematology annual meeting, Atlanta, Georgia; Blood 2012; 120;
- 2018 Invited speaker – Aberrant splicing in patients with myeloma is associated with modulated expression of 2nd international conference in splicing, Caparica, Portugal.
Current Courses |
Course Catalog |
|---|---|
2020-2021 Year Doctoral level
|